Page 31 - Journal of Structural Heart Disease Volume 5, Issue 1

Case Report
20
of post–operative patients with tetralogy of Fallot, who had transannular patch augmentation of RVOT. Recently, Cao et al [2], Promphan et al [3], and Garay et al [4] reported on their preliminary experience in humans using the Venus P–valve under Institutional approved protocols (the valve is not CE marked or FDA approved) with satisfactory early results. In this report a Melody and Venus P-valves were implanted sequentially in the rare case of a patient with post-op- erative TOF for the treatment of progressive dysfunc- tion of an artificial and native RVOT, respectively. The procedures were successful with no complications and the patient was discharged the next day in ex- cellent clinical condition. Fluoroscopy performed six months after the procedure, showed well-positioned valves with no fractures. Echocardiographic evalu- ation at the 1-year follow-up demonstrated a com- petent Venus P-valve with a small residual gradient across the RVOT. CMR follow-up showed significant improvement in RV volume and function parameters. Up to now approximately 110 Venous-P valves have been implanted worldwide with excellent short term results [5]. It should be noted that the Venous P- valve is being evaluated in CE trial for the assessment of its efficacy and safety.
Conclusions
Double PPVI can be used safely and effectively as an alternative to surgery for the treatment of select- ed post-operative patients with TOF and combined dysfunction of the native and surgically placed RVOT conduit. The Venus P-valve adds to our armamentar-
Figure 3. Fluoroscopic image six months after the Venus P-valve and Melody® valve implantation demonstrating absence of stent fractures.
ium for the treatment of patients with larger outflow tracts following surgical repair.
Conflict of Interest
The authors have no conflict of interest relevant to this publication.
Comment on this Article or Ask a Question
References
1. Asari MM, Cardoso R, Garcia D, Sandhu
S, Horlick E, et al. Percutaneous pulmo-
nary valve implantation. Present status
and evolving feature. J Am Coll Cardi-
ol. 2015;66:2246–2255. DOI: 10.1016/j. 4. jacc.2015.09.055
pulmonary valve implantation with the Venus P-valve: clinical experience and ear- ly results. Cardiol Young. 2015;26:698–710. DOI: 10.1017/S1047951115001067
Garay F, Pan X, Zhang YJ, Wang C, Spring- muller D. Early experience with the Venous P-valve for percutaneous pulmonary valve implantation in native pulmonary valve implantation in native outflow tract. Neth Heart J. 2O17;25:76-81. DOI: 10.1007/ s12471-016-0932-5
Alkashkari W, Alrahimi J, Albugami S, Cao QL, Hijazi ZM. Transcatheter pulmonary valve replacement: The Venous-P valve current
status. Structural Heart Disease. 2018;4:1-8. DOI: 10.12945/j.jshd.2018.035.17
2. Cao Q, Kenny D, Zhou D, Pan W, Guan L, Ge J, et al. Early clinical experience with a novel self-expanding percutaneous stent-valve in the native right ventricular outflow tract. Catheter Cardiovasc Interv. 2014;84:1131– 1137. DOI: 10.1002/ccd.25544
3. Promphan W, Prachasilchai P, Siripornpitak S, Qureshi SA, Layangool T. Percutaneous
5.
Cite this article as: Thanopoulos BD, Dardas P, Kallifatidis A, Quireshi SA. Percutaneous Implantation of Venus P-Valve and Melody Valve in a Patient with Dysfunctional Native and Artifi- cial Right Ventricular Outflow Tracts. Structural Heart Disease. 2019;5(1):16- 20. DOI: https://doi.org/10.12945/j. jshd.2019.024.18
Journal of Structural Heart Disease, February 2019
Volume 5, Issue 1:16-20